Peptides for epilepsy: the GABA and glutamate balance - A Clinica...

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Epilepsy, affecting 1 in 26 Americans, often stems from an imbalance between excitatory glutamate and inhibitory GABA neurotransmission, with conventional AEDs failing nearly a third of patients. Peptides like DSIP and NPY show promise by modulating GABAergic activity, while somatostatin can curb glutamatergic overactivity, offering targeted avenues for therapeutic intervention in refractory cases.

Approximately 1 in 26 people in the United States will develop epilepsy at some point in their lifetime, making it one of the most common neurological disorders globally [1]. While antiepileptic drugs (AEDs) are the cornerstone of treatment, nearly one-third of patients continue to experience seizures, highlighting the critical need for novel therapeutic strategies [2]. Emerging research points towards specific peptides as potential modulators of the delicate balance between excitatory (glutamate) and inhibitory (GABA) neurotransmission, a dysregulation central to seizure generation.

The brain's electrical activity is a finely tuned symphony, with GABA acting as the primary inhibitory neurotransmitter, dampening neuronal excitability, and glutamate as the main excitatory one, promoting it. In epilepsy, this balance often tips towards hyperexcitability. Peptides offer a unique avenue for intervention due to their high specificity and diverse mechanisms of action, often targeting G-protein coupled receptors or ion channels.

Modulating GABAergic Transmission: The Role of Peptides

One compelling peptide in this context is delta sleep-inducing peptide (DSIP). Clinically, DSIP has shown promise in reducing seizure frequency and severity in some refractory epilepsy patients, particularly those with generalized tonic-clonic seizures. Studies have explored doses ranging from 10-30 nmol/kg administered intravenously, often over several weeks, with some patients reporting sustained reductions in seizure activity for months after a course of treatment [3]. Its mechanism isn't fully elucidated, but it's thought to enhance GABAergic transmission and modulate opioid receptor activity, contributing to its anticonvulsant effects. However, not all patients respond, and a significant portion may see only transient benefits, suggesting individual neurochemical profiles play a crucial role.

Another fascinating area involves neuropeptide Y (NPY). NPY is an endogenous peptide found abundantly in the brain, and it's known to exert potent anticonvulsant effects in various animal models of epilepsy [4]. It primarily acts through Y1 and Y2 receptors, leading to reduced glutamate release and enhanced GABAergic inhibition. For instance, intracerebroventricular administration of NPY at doses of 1-10 µg has been shown to suppress seizures in kainate-induced epilepsy models in rats, with effects lasting several hours [5]. The challenge with NPY lies in its poor blood-brain barrier penetration, making systemic administration less effective for direct brain targeting. Researchers are exploring NPY analogs or delivery systems to overcome this hurdle.

Targeting Glutamatergic Overactivity: A Peptide Approach

While enhancing inhibition is one strategy, curbing excessive excitation is another. Glutamate, while essential for learning and memory, becomes neurotoxic and pro-convulsant when its levels are unregulated. Peptides that modulate glutamate release or receptor activity are of significant interest.

Somatostatin (SST), a cyclic peptide, is an endogenous inhibitor of neuronal excitability and has demonstrated anticonvulsant properties. SST primarily acts via G-protein coupled receptors, leading to reduced presynaptic glutamate release and hyperpolarization of neurons. In animal models, intrahippocampal injections of SST have been shown to significantly decrease seizure duration and frequency in response to convulsant agents [6]. Doses in the picomolar range have produced notable effects, suggesting its potent neuromodulatory capacity. However, SST's short half-life and widespread physiological effects outside the brain limit its direct clinical application for epilepsy at present. Synthetic analogs with improved pharmacokinetics and targeted delivery are under investigation.

Comparing DSIP and NPY, you'll find that DSIP appears to have a more direct impact on sleep architecture and a broader neuromodulatory role, potentially influencing multiple neurotransmitter systems, whereas NPY's anticonvulsant effects are more directly linked to its role in regulating neuronal excitability via specific receptor subtypes. While both aim to restore balance, their primary mechanisms of action differ, with DSIP potentially acting upstream on regulatory pathways and NPY more directly on synaptic transmission.

Clinical Takeaway

For patients with refractory epilepsy, particularly those who haven't responded adequately to conventional AEDs, exploring novel peptide-based strategies that target the GABA-glutamate balance holds significant promise. While many of these peptides are still in preclinical or early-phase clinical trials, DSIP, given its existing clinical use for sleep disorders, might be considered in highly selected cases under strict medical supervision, starting with low-dose IV infusions (e.g., 10 nmol/kg) and carefully monitoring seizure diaries and EEG changes over a 4-8 week period to assess efficacy and tolerability.

References